Aurobindo Pharma arm gets exclusive rights for BioFactura monoclonal antibody ustekinumab biosimilar

Aurobindo Pharma Ltd., a prominent pharmaceutical company, announced on Friday, July 7, that CuraTeQ Biologics Private, a wholly-owned subsidiary, has inked an exclusive licencing deal with the US-based BioFactura to commercialise BFI-751, a potential biosimilar to Stelara.

Ustekinumab is a recombinant monoclonal antibody used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. It acts by blocking the interleukins IL-12 and IL-23.

Ustekinumab had close to $10 billion in global medication sales in 2022, the business reported in an exchange filing, offering a sizable prospect with a good range of indications and wider use.

According to the terms of the agreement, CuraTeQ has been given the sole right to commercialise BFI-751 in the US, EU, UK, Canada, ANZ, and a few other semi-regulated and developing markets across the world. The product will be manufactured at CuraTeQ facilities in Hyderabad, India, and will also have global manufacturing rights, according to the business.

Source: Media reports